Related Experiment Video
Updated: Aug 11, 2026
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
The future of cell therapy for acute myocardial infarction
1Division of Cardiovascular Diseases & Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN, USA. n.caplice@ucc.ie
Insights
Bone-marrow-derived mononuclear cell therapy shows modest cardiac improvements after myocardial infarction. Future research should explore simplified procedures, earlier interventions, and integration with revascularization techniques.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Cell Therapy
Background:
- Initial clinical trials using bone-marrow-derived mononuclear cells post-acute myocardial infarction (AMI) demonstrated improvements in cardiac function.
- Observed functional gains, such as augmented left ventricular function, have been modest (6-8%).
- Significant debate exists regarding optimal cell populations, isolation methods, and the underlying mechanisms of therapeutic benefit.
Purpose of the Study:
- To address critical questions for large-scale, randomized trials in AMI cell therapy.
- To investigate the potential for simplified cell therapy procedures and earlier therapeutic effects.
- To explore alternatives to exogenous cell processing, such as mobilizing endogenous cells, and integration with interventional approaches.
Main Methods:
- The abstract does not detail specific experimental methods but discusses conceptual approaches for future research.
- Focuses on evaluating paracrine factors, locally mobilized progenitor cells, and integration with interventional technologies.
Main Results:
- Initial studies indicate modest functional improvements following bone-marrow-derived mononuclear cell therapy for AMI.
- The abstract highlights ongoing debates and unanswered questions rather than definitive results.
Conclusions:
- Further research is needed to optimize cell therapy for AMI, focusing on efficacy, logistics, and mechanisms.
- Emerging concepts suggest paracrine factors, endogenous cell mobilization, and combination therapies with interventional approaches may enhance outcomes.
Abstract:
Initial clinical trials of bone-marrow-derived mononuclear cells after acute myocardial infarction have shown improvement in a number of cardiac indices, including left ventricular systolic function, infarct size, stroke volume, and coronary blood flow. Functional improvements observed in cell therapy studies have been modest, with augmentation of left ventricular function in the range of 6-8%. Nevertheless, these studies have generated considerable debate on a number of issues, including the efficacy of specific cell populations, logistics of cell harvesting and isolation, and, most importantly, the mechanism of cell therapy benefit. With the field on the threshold of large-scale, randomized, controlled clinical trials, additional questions, such as the following, must be asked. Can cell therapy procedures be simplified? Can therapeutic effects be obtained earlier after myocardial infarction? Is cell harvesting a necessary component of cell therapy or can endogenous cells be mobilized sufficiently to obviate the need for processing exogenous cells? In an era when interventional devices are increasingly used in therapeutic approaches to acute myocardial infarction, can current cell therapy practice be integrated with interventional approaches to acute revascularization? Emerging concepts that may address some of these questions include whether paracrine factors released by progenitor or stem cells can be as efficacious as bone-marrow- or blood-derived cells, whether novel progenitor populations mobilized locally in the vessel wall or the heart can participate in repair or regeneration, and whether cell therapy strategies for acute myocardial infarction will evolve to include interventional technologies in combination with paracrine or mobilization factors.
